MacroGenics (MGNX) Competitors $2.76 -0.12 (-4.17%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.76 +0.01 (+0.18%) As of 02/21/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MGNX vs. CRMD, ABUS, PHAR, IMTX, ORIC, RAPP, SEPN, PGEN, STOK, and CGEMShould you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include CorMedix (CRMD), Arbutus Biopharma (ABUS), Pharming Group (PHAR), Immatics (IMTX), ORIC Pharmaceuticals (ORIC), Rapport Therapeutics (RAPP), Septerna (SEPN), Precigen (PGEN), Stoke Therapeutics (STOK), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. MacroGenics vs. CorMedix Arbutus Biopharma Pharming Group Immatics ORIC Pharmaceuticals Rapport Therapeutics Septerna Precigen Stoke Therapeutics Cullinan Therapeutics MacroGenics (NASDAQ:MGNX) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, community ranking, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Do institutionals and insiders believe in MGNX or CRMD? 96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 11.3% of MacroGenics shares are owned by insiders. Comparatively, 5.2% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, MGNX or CRMD? MacroGenics has higher revenue and earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMacroGenics$58.75M2.95-$9.06M-$1.58-1.75CorMedix$60K10,244.81-$46.34M-$0.81-12.51 Does the media refer more to MGNX or CRMD? In the previous week, MacroGenics had 2 more articles in the media than CorMedix. MarketBeat recorded 3 mentions for MacroGenics and 1 mentions for CorMedix. MacroGenics' average media sentiment score of 0.22 beat CorMedix's score of 0.00 indicating that MacroGenics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer MGNX or CRMD? MacroGenics received 401 more outperform votes than CorMedix when rated by MarketBeat users. However, 75.76% of users gave CorMedix an outperform vote while only 62.28% of users gave MacroGenics an outperform vote. CompanyUnderperformOutperformMacroGenicsOutperform Votes42662.28% Underperform Votes25837.72% CorMedixOutperform Votes2575.76% Underperform Votes824.24% Is MGNX or CRMD more profitable? CorMedix has a net margin of 0.00% compared to MacroGenics' net margin of -69.07%. CorMedix's return on equity of -79.21% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets MacroGenics-69.07% -89.42% -38.57% CorMedix N/A -79.21%-64.68% Do analysts rate MGNX or CRMD? MacroGenics presently has a consensus price target of $7.63, indicating a potential upside of 176.27%. CorMedix has a consensus price target of $15.67, indicating a potential upside of 54.66%. Given MacroGenics' higher probable upside, equities analysts plainly believe MacroGenics is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36CorMedix 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, MGNX or CRMD? MacroGenics has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. SummaryMacroGenics beats CorMedix on 11 of the 18 factors compared between the two stocks. Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGNX vs. The Competition Export to ExcelMetricMacroGenicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$180.76M$7.07B$5.85B$9.15BDividend YieldN/A2.76%4.76%3.85%P/E RatioN/A2.5616.5114.19Price / Sales2.95304.55450.0276.60Price / CashN/A65.6738.0134.95Price / Book1.126.717.644.63Net Income-$9.06M$138.11M$3.18B$245.69M7 Day Performance7.81%-2.54%-1.95%-2.68%1 Month Performance-10.39%-2.00%-0.23%-2.16%1 Year Performance-83.87%-5.04%16.69%12.90% MacroGenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGNXMacroGenics3.5751 of 5 stars$2.76-4.2%$7.63+176.3%-83.8%$180.76M$58.75M0.00430News CoverageCRMDCorMedix1.325 of 5 stars$10.48+0.4%$15.67+49.5%+211.7%$635.90M$12.26M-12.9430News CoveragePositive NewsABUSArbutus Biopharma1.6623 of 5 stars$3.29-0.3%$5.50+67.2%+18.9%$623.42M$18.14M-7.6590PHARPharming Group2.9343 of 5 stars$9.13+3.2%$27.00+195.7%-19.7%$621.19M$285.75M-35.12280Positive NewsGap UpIMTXImmatics1.6069 of 5 stars$5.05-0.8%$16.67+230.0%-61.7%$602.77M$58.44M-7.65260ORICORIC Pharmaceuticals4.5393 of 5 stars$8.36+1.1%$18.71+123.9%-25.6%$589.97MN/A-4.6480Earnings ReportAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeRAPPRapport Therapeutics1.8127 of 5 stars$15.90+0.8%$35.00+120.1%N/A$581.62MN/A0.00N/AUpcoming EarningsSEPNSepterna2.177 of 5 stars$12.96+12.2%$43.67+236.9%N/A$575.42MN/A0.00N/AAnalyst DowngradeAnalyst RevisionNews CoverageGap UpPGENPrecigen3.954 of 5 stars$1.96-1.0%$7.00+257.1%+34.5%$574.03M$6.22M-3.56190Gap UpSTOKStoke Therapeutics3.7038 of 5 stars$10.68+0.5%$21.29+99.3%+55.4%$565.72M$8.78M-5.09100Analyst ForecastAnalyst RevisionNews CoverageCGEMCullinan Therapeutics2.3347 of 5 stars$9.53-0.6%$32.50+241.0%-47.1%$554.93MN/A-3.3630 Related Companies and Tools Related Companies CorMedix Alternatives Arbutus Biopharma Alternatives Pharming Group Alternatives Immatics Alternatives ORIC Pharmaceuticals Alternatives Rapport Therapeutics Alternatives Septerna Alternatives Precigen Alternatives Stoke Therapeutics Alternatives Cullinan Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MGNX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
